Working… Menu
Trial record 8 of 135 for:    AMITRIPTYLINE

Treatment of Chronic Laryngitis With Amitriptyline

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02552225
Recruitment Status : Enrolling by invitation
First Posted : September 17, 2015
Last Update Posted : October 22, 2019
American Laryngological Association
Information provided by (Responsible Party):
Boston Medical Center

Brief Summary:
This randomized, double-blind, placebo-controlled trial will compare the effectiveness of amitriptyline versus placebo (inactive medication) in treating chronic laryngitis.

Condition or disease Intervention/treatment Phase
Laryngeal Diseases Drug: Amitriptyline Other: Placebo Phase 2 Phase 3

Detailed Description:

Chronic laryngitis commonly manifests through symptoms including cough, hoarseness, throat clearing, foreign body sensation, throat pain, sensation of excessive phlegm, and difficulty swallowing. A significant minority also present with GERD, rhinosinusitis-induced post-nasal drainage, direct allergic effect, and smoking issues.

Amitriptyline is commonly used for mental/mood problems, but is also prescribed to treat chronic laryngitis because some investigators suggest a neuropathic etiology for idiopathic chronic laryngitis. No trials have compared any treatment for chronic laryngitis to placebo and it is unknown if currently used therapies for chronic laryngitis are effective.

At the baseline visit, subjects will be assigned at random to amitriptyline or placebo, which they will take for 4 weeks each. Subjects will be seen in the clinic at baseline and after 10 weeks. Improvement will be measured using standardized symptom scales, and a self-reported subjective improvement percentage.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 138 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Double-blind Placebo Controlled Trial of the Treatment of Chronic Laryngitis With Amitriptyline
Actual Study Start Date : April 2016
Estimated Primary Completion Date : October 2022
Estimated Study Completion Date : October 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: amitriptyline
Subjects in this arm will receive pills composed of amitriptyline and Avicel (cellulose filler)
Drug: Amitriptyline
Subjects in this arm will receive pills composed of amitriptyline and Avicel (cellulose filler)
Other Name: Elavil

Placebo Comparator: placebo
Subjects in this arm will receive pills composed only of Avicel (cellulose filler)
Other: Placebo
Subjects in this arm will receive pills composed only of Avicel (cellulose filler)

Primary Outcome Measures :
  1. Score on modified Reflux Symptom Index (RSI) [ Time Frame: 10 weeks ]
    The Reflux Symptom Index (RSI) is a validated questionnaire consisting of 9 statements to be ranked on a scale of 0-5 (0=no problem, 5=severe problem). The RSI has been modified with the addition of two statements ("throat pain or burning" and "pain with swallowing") since those may be relevant to chronic laryngeal neuropathy. Patients will answer the questionnaire based on any symptoms they have been experiencing within the last month.

Secondary Outcome Measures :
  1. Score on modified Voice Handicap Index-10 (VHI-10) [ Time Frame: 10 weeks ]
    The Voice Handicap Index-10 (VHI-10) is a 10-question scale rated from 0-4 that addresses effects on quality of life from voice disorders (0=never, 1=almost never, 2=sometimes, 3=almost always, 4=always).

  2. Number of patients with side effects [ Time Frame: 10 weeks ]
    Count of patients who report side effects due to the treatment.

  3. Number of patients discontinuing treatment due to side effects [ Time Frame: 10 weeks ]
    Count of patients who discontinue treatment and drop out of study due to the treatment side effects.

  4. Subjective percentage improvement in symptoms [ Time Frame: 10 weeks ]
    Patients will subjectively rate improvement in symptoms by percentage by comparing pre-treatment (baseline) to post-treatment symptoms after 8 weeks. Patients will report if symptoms ar ebetter, worse, or same after treatment.

  5. Frequency of side effect by category [ Time Frame: 10 weeks ]
    Patients will describe subjective side effects experienced, such as dry mouth, sedation, and dizziness.

  6. Score on the Cough Severity Index [ Time Frame: 10 weeks ]
    The Cough Severity Index is a validated questionnaire using a 10-item likert scale to quantify a patient's symptoms associated with upper airway chronic cough.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Must be age 18 or older and able to consent for themselves
  2. Must have had structural pathology such as tumor previously ruled out using flexible laryngoscopy
  3. Must be able to speak and read the English language
  4. Must have failed a 2 month or longer trial of a proton pump inhibitor for the treatment of gastro-esophageal reflux
  5. Women under 55 years of age who may become pregnant must have a negative pregnancy test and agree to barrier or hormonal methods of contraception during the study

Exclusion Criteria:

  1. Environmental allergies
  2. Smoking within past 5 years
  3. Upper respiratory infections within the past 2 months
  4. Use of narcotics (e.g. oxycodone, methadone) within the past week
  5. Any prior history of amitryptiline use
  6. Use of any other monoamine oxidase inhibitors (MAOIs) other than amitryptiline within the past 4 weeks (selegiline, phenelzine, tranylcypromine, isocarboxazid, rasagiline, phenelzine sulfate, selegiline hydrochloride, rasagiline mesylate, tranylcypromine sulfate)
  7. History of urinary retention
  8. Any history of major depressive disorder
  9. Any prior history of allergy to a tricyclic antidepressant
  10. Current diagnosis of gastroesophageal reflux (GERD)
  11. For women 18-55 years of age without history of menopause: currently nursing or pregnant, plans to become pregnant, or unwillingness to utilize contraception (barrier or hormonal methods)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02552225

Layout table for location information
United States, Massachusetts
Boston Medical Center
Boston, Massachusetts, United States, 02118
Sponsors and Collaborators
Boston Medical Center
American Laryngological Association
Layout table for investigator information
Principal Investigator: J. Pieter Noordzij, MD Boston Medical Center

Layout table for additonal information
Responsible Party: Boston Medical Center Identifier: NCT02552225     History of Changes
Other Study ID Numbers: H 34438
First Posted: September 17, 2015    Key Record Dates
Last Update Posted: October 22, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Boston Medical Center:
laryngeal sensory neuropathy, chronic laryngeal neuropathy
Additional relevant MeSH terms:
Layout table for MeSH terms
Amitriptyline, perphenazine drug combination
Laryngeal Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Antidepressive Agents, Tricyclic
Antidepressive Agents
Psychotropic Drugs
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Neurotransmitter Agents
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants